AzTrials
AzTrials

Fish AllergyTRO-FASTNCT02365168

Allergy Against Different Species of Fish in Children and Adolescents Allergic to Fish

A study of Fish Allergy, run by University Hospital of North Norway at 2 sites in Norway.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Study hypothesis: Some children and adolescents with fish allergy can tolerate eating some species of fish Purpose of the study: The purpose of this study is to determine to which degree fish allergic children and adolescents can tolerate some species of fish and find the minimal eliciting allergen dose to which only… Read more about this study

Who is it for?
Ages 5 to 20 years
Conditions the study is for
Fish Allergy
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
44 participants
Where
2 sitesNorway
Study dates
Sep 2014to Sep 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 20 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Known or suspected allergy to fish with either positive specific s-IgE or skin prick test to one or more fish species
  • Either positive specific s-IgE or spin prick test to one or more fish species and never eaten fish.

Who cannot join

  • Serious chronic disease

Trial locations and contacts

2 sites in 1 country.

Norway2 sites
  • University Hospital of North Norway

    Tromsø, 9013

  • University Hospital of North Norway

    Tromsø

Other trials in Norway

About this study

Study hypothesis:

Some children and adolescents with fish allergy can tolerate eating some species of fish

Read more

Purpose of the study:

The purpose of this study is to determine to which degree fish allergic children and adolescents can tolerate some species of fish and find the minimal eliciting allergen dose to which only 10% of participants get allergic reaction.

Participants:

Participants are 40 patients recruited from children and adolescents outpatient clinics at the University Hospital of North Norway with a history of fish allergy and sensibilisation of one or more fish species with either positive specific IgE in serum or skin prick test. Patients with sensibilisation to one or more fish species that never have eaten fish are also recruited.

Method:

  • All participants undergo a clinical examination including lung function test with spirometry before inclusion in the study.
  • All participants are tested for allergic sensibilisation with measure of specific IgE against common food and inhalation allergens in addition to 10 different fish species.
  • All participants are challenged with cod, salmon, mackerel and placebo, disguised in a chocolate mousse. The challenges are performed in randomized order with Double Blind Placebo Controlled Food Challenge (DBPCFC) on 4 different challenge days with minimum 6 weeks in between each challenge day.
  • Participant with allergy to pollen will not be challenged during pollen season.
  • Test food is developed especially to this study in cooperation with The National Institute of Food Research in Norway and The University of Manchester. The National Institute of Food Research in Norway have produced a dried powder of cod, salmon and mackerel. The "Molecular Allergology group at Manchester Institute of Biotechnology, the University of Manchester, have produced test kits based on chocolate mousse containing low and high doses of the fish powders. The National Institute of Food Research have measured protein content and microbiology in the fish powders. The Molecular Allergology group have provided quality measurements of the final product and tested the disguise in a sensoric test panel.
  • Participants with no allergic reaction to one or more of the blinded challenges undergo open food challenge with larger doses of cooked fish than used in the DBPCFC, after the randomization has been broken.
Read the detailed description

Introduction:

Fish have an important role in human food providing a valuable source of highly assimilated proteins and consumption of fish is increasing all over the world. Fish allergy is one of the most common food allergies together with milk, egg, nuts, peanuts, fruits, wheat, soy and seafood. It is more common in coastal countries and countries with traditions in fish industry and where fish plays an important role in food traditions. This is the situation in Northern Norway where fishing and fish industry have been the most important way to make a living and fish an important part of the food. Allergy to fish is particularly common in children and young adults. The symptoms related to fish allergy vary from mild symptoms to anaphylaxis. Most patients with fish allergy avoid all species of fish and health care workers often advice them to do so. The major allergen in fish is a muscle parvalbumin resistant to heat, chemical denaturation and proteolytic enzymes. Due to homology in the amino acid sequence in parvalbumins in different fish species, cross-reactivity exists.

However, clinical experience, studies on sensibilisation, and some open food challenge studies indicates that some patients with fish allergy can tolerate some species of fish. The main purpose of this study is to find to which degree fish allergic children and adolescents can tolerate some species of fish, using DBPCFC as the gold standard in diagnosis of food allergy, and thereby avoid unnecessary food restrictions in their diet.

The food industry often label their products with "main contain allergen" because they lack information about threshold doses for allergic reactions. Unnecessary labeling of food results in less variation in the diet for food allergic patients. Another purpose of this study is to find the Minimal Eliciting Dose to which 10% of the participants get allergic reaction, and thereby contribute to a more precise labeling of food.

Method:

DBPCFC is the gold standard in the diagnosis of food allergy. To disguise the taste and smell from fish in a standardized test food with good taste and texture is difficult. It is especially difficult with children, who are less likely to eat food with bad taste and where the volume of test food they can manage is limited.

In cooperation with The National Institute of Food Research in Norway we have produced dried fish powders from cod, salmon and mackerel. Frozen filets have been cooked, dried and made into powders. The powders have been checked for microbiologic content and protein content. The procedure involves removing as much fat as possible. The powders are stored in a freezer with a temperature of -20°C. The volume is decreased with about 80% compared with cooked fish.

In cooperation with Professor Clare Mills in the Molecular Allergology group, Manchester Institute of Biotechnology, The University of Manchester, the fish powders is put into a chocolate dessert based on a recipe used in a EuroPrevall study on food allergy. The production of chocolate desserts is performed at the University of Manchester together with quality check regarding allergen content, content of parvalbumin, microbiology and speciation of the fish. The disguise of taste and smell are tested in a sensoric test panel.

Recruitment of participants:

Patients aged 5-20 yr, with a history of fish allergy and sensibilisation to fish who had visited one of the outpatient clinics for children and adolescents at the university hospital of Northern Norway, are invited to participate. Patients with sensibilisation to fish that never have eaten fish are also invited. In addition, patients registered with sensibilisation against cod at the allergology lab, University Hospital of Northern Norway since 2008 , that not already had been picked up from an outpatient clinic is invited to participate. The laboratory is the only allergology laboratory in the region the participants are recruited from.

Examination before inclusion:

All patients that give their consent to participate undergo clinical examination, including spirometry, before inclusion to ensure eligibility. The clinical examination contains measurements of weight and height, heart and lung auscultation, examination of skin, conjunctiva, nose and oral cavity.

Special attention is given to uncontrolled asthma and eczema and to ensure optimized treatment before inclusion. Pollen allergic patients will not undergo food challenges during pollen season.

Measurement of specific Immunoglobulin E (IgE) in serum:

In all participants, specific IgE in serum against the following allergens are measured:

  1. Fx5 (Egg, milk, cod, wheat, soy, peanut)
  2. Inhalation panel 6 (Birch, timothy, mugwort, alternaria, cladosporium)
  3. Inhalation panel 7(Cat, horse, dog, house dust mite, rabbit)
  4. Gad c1, f426 (Parvalbumin from cod)
  5. Cyp c1, f355 (Parvalbumin from carp)
  6. Salmon, f41
  7. Mackerel, f206
  8. Halibut, f303
  9. Pollock, f413
  10. Haddock, f42
  11. Herring, f205
  12. Plaice,4254
  13. Tuna, f40
  14. Shrimp,f24
  15. f351 (recombinant shrimp tropomyosin)

Questionnaire:

Parents answer a questionnaire for research in allergy. The questionnaire is translated to Norwegian and an electronic survey is used. The parents answer the questionnaire during the first challenge day. The questionnaire is extended with questions regarding fish allergy.

Double Blind Placebo Controlled Food Challenge with cod, salmon, mackerel and placebo:

All participants undergo DBPCFC with cod, salmon, mackerel and placebo in randomized order, disguised in a chocolate dessert on 4 separate challenge days with minimum 6 weeks between each challenge day. Participants that have experienced anaphylaxis, verified and treated in hospital , are not challenged with the species that have given anaphylaxis. Symptoms are recorded on a clinical manifestations record sheet based on a protocol from the University Hospital of South Manchester with grading of the symptoms and defined stop criteria. The protein doses are based on the experience of a EuroPrevall study with DBPCFC with cod:

3µg, 600µg, 12mg, 120mg and1g for DBPCFC

Open challenges with cod and/or salmon and mackerel:

Participants that have no allergic reactions after DBPCFC with either cod, salmon and mackerel, undergo open challenge(s) with 2 g, 6 g and 12 g of protein , served as cooked fish, with the species that gave negative DBPCFC. The open challenges are done on separate days after the randomization code has been broken.

Ceasing of medication before DBPCFC and open challenges:

Systemic corticosteroid therapy are ceased at least one week before challenges. Antihistamine treatment are ceased at least 72 hours before the challenges. Short acting β-2 agonists are ceased at least 6 hours before the challenges and Long acting β-2 agonists at least 24 hours before the challenges. Participants are allowed to continue inhalant corticosteroids and leukotriene receptor antagonists.

Postponing of DBPCFC and open challenges:

The challenges are postponed if the participants have ongoing infections, ongoing allergic reactions, uncontrolled eczema or uncontrolled asthma. Participants with pollen allergy are not challenged during pollen season.

Observation and treatment of allergic reactions:

All fish challenges are performed at the research unit at the University Hospital of North Norway in the period of September 2014 - February 2015. Two participants are challenged each challenge day and all participants are observed by one blinded research nurse. Unblinded staff prepare the test meals every morning. One blinded doctor examines the participants before, during and after the challenges and decides whether challenges are positive or negative. The challenges are stopped if participants develop objective signs of allergic reactions. Stop criteria are predefined. Participants are observed in the hospital at least two hours after the challenges have been stopped. Allergic and anaphylactic reactions are treated according to European Academy of Allergology and Clinical Immunology position paper of Anaphylaxis. Participants are contacted by blinded research nurse by phone next day to record late reactions after discharge.

Conditions
Fish Allergy
Being tested
Cod_Double Blind Placebo Controlled Food Challenge, Salmon_Double Blind Placebo Controlled Food Challenge, Mackerel_Double Blind Placebo Controlled Food Challenge, Placebo_Double Blind Placebo Controlled Food Challenge
Keywords
Fish allergy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cod_Double Blind Placebo Controlled Food ChallengeOther

    Also called DBPCFC with cod

    DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day

  • Salmon_Double Blind Placebo Controlled Food ChallengeOther

    Also called DBPCFC with Salmon

    DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day

  • Mackerel_Double Blind Placebo Controlled Food ChallengeOther

    Also called DBPCFC with Mackerel

    DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day

  • Placebo_Double Blind Placebo Controlled Food ChallengeOther

    Also called DBPCFC with placebo

    DBPCFC Food Challenge with placebo covered in chocholate dessert over one day

Study groups in NCT02365168
Study groupRoleWhat they receive
Food Challenge with codExperimentalNot described
Receives: Other: Cod_Double Blind Placebo Controlled Food Challenge
Food Challenge with salmonExperimentalNot described
Receives: Other: Salmon_Double Blind Placebo Controlled Food Challenge
Food Challenge with mackerelExperimentalNot described
Receives: Other: Mackerel_Double Blind Placebo Controlled Food Challenge
Food Challenge with placeboPlacebo comparatorNot described
Receives: Other: Placebo_Double Blind Placebo Controlled Food Challenge

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Allergic response to fish allergens with dosing escalation

    Symptoms are recorded on a clinical manifestations record sheet based on a protocol from the University Hospital of South Manchester with grading of the symptoms and defined stop criteria.

    Measured: Within two hours after last dosage

Secondary outcomes (1)
  1. Correlation coefficient between specific IgE to fish allergens and allergic response

    Measurement of spesific IgE at baseline and allergic response up to one day after the challenge

    Measured: One day after exposure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2015 (estimated)
  2. Study startSep 2014
  3. Primary completionSep 2015
  4. Study completionSep 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
44 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02365168
Sponsor's protocol ID
2013/757(REK)
Acronym
TRO-FAST
Status last verified
Dec 2015
First submitted
19 Aug 2014
Last updated
15 Dec 2015
Results posted
No
Data monitoring committee
No

Publications

  • Lopata AL, Lehrer SB. New insights into seafood allergy. Curr Opin Allergy Clin Immunol. 2009 Jun;9(3):270-7. doi: 10.1097/ACI.0b013e32832b3e6f.

    PubMed 19398906
  • Tsabouri S, Triga M, Makris M, Kalogeromitros D, Church MK, Priftis KN. Fish and shellfish allergy in children: review of a persistent food allergy. Pediatr Allergy Immunol. 2012 Nov;23(7):608-15. doi: 10.1111/j.1399-3038.2012.01275.x. Epub 2012 May 3.

    PubMed 22554093

Questions about this trial

What is this clinical trial studying?

A study of Fish Allergy, run by University Hospital of North Norway at 2 sites in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Allergic response to fish allergens with dosing escalation (time frame: Within two hours after last dosage). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02365168, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in